Venous Thrombosis in Older People: Prevalence of the Factor V Gene Mutation Q506
- 1 December 1998
- journal article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 46 (12), 1545-1549
- https://doi.org/10.1111/j.1532-5415.1998.tb01540.x
Abstract
OBJECTIVES: Old age is usually considered to be a risk factor for venous thromboembolism, in conjunction with other factors such as heart failure, major surgery, cancer, long‐term immobilization, and antiphospholipid antibodies. Genetic risk factors, especially inherited deficiencies in coagulation inhibitors, also play a role in the pathogenesis of thrombosis, but these are usually diagnosed in thrombophilic patients before the age of 50. The factor V Q506 mutation, responsible for activated protein C resistance, was recently linked to thromboembolic disease. We therefore investigated the prevalence of biological risk factors in older hospital patients with venous thromboembolism. DESIGN: A 2‐year study period. SETTING: Ivry sur Seine (Paris), France. PARTICIPANTS: Seventy‐nine geriatric patients (60 women and 19 men, mean age 83 ± 6.8 years, range 70–102 years) who had had at least one proven episode of venous thromboembolism were enrolled over a 2‐year period. MEASUREMENTS: Lupus anticoagulant and antithrombin (AT), protein C (PC), and protein S (PS) levels were determined in plasma. The factor V Q506 mutation was detected on genomic DNA. RESULTS: Lupus anticoagulant was detected in two women, one of whom also had a high level of anticardiolipin IgG, leading to the diagnosis of an antiphospholipid syndrome. No hereditary deficiency in AT, PC, or PS was found, but one patient had an acquired AT deficiency. Interestingly, nine of the 79 patients (11.4%, six women and three men) were heterozygous for the factor V Q506 mutation, although none were homozygous. The only major risk factor for thrombosis identified in these patients was prolonged immobilization in four cases. Four of the nine patients who were heterozygous for the factor V Q506 mutation had recurrent thromboembolism, and two of these patients had been immobilized for long periods. CONCLUSIONS: This study confirms that hereditary deficiencies in coagulation inhibitors, and the lupus anticoagulant, are rarely involved in the pathogenesis of venous thromboembolism in older subjects. In contrast, the factor V Q506 mutation was frequently associated with thrombosis (11.4% of our patients) and should, therefore, be considered an important risk factor in the older people.Keywords
This publication has 18 references indexed in Scilit:
- Antiphospholipid antibodies and the antiphospholipid antibody syndromeJournal of the American Academy of Dermatology, 1997
- Resistance to activated protein C: role in venous and arterial thrombosisBiomedicine & Pharmacotherapy, 1996
- The Population Genetics of Factor V Leiden (Arg506Gln)British Journal of Haematology, 1996
- Activated protein C resistance as a basis for venous thrombosisThe American Journal of Medicine, 1996
- A rapid screening method for the factor V Arg506???Gln mutationBlood Coagulation & Fibrinolysis, 1995
- Activated protein C resistance caused by Arg506Gln mutation in factor VaThe Lancet, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Resistance to Activated Protein C as a Basis for Venous ThrombosisNew England Journal of Medicine, 1994
- Inherited resistance to activated protein C iscorrected by anticoagulant cofactor activity found to be a property of factorV.Proceedings of the National Academy of Sciences, 1994
- Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.Proceedings of the National Academy of Sciences, 1993